Drug Details

General Information of the Drug (ID: DR6730)
Name
10058F4
Synonyms
10058-F4; 403811-55-2; (5E)-5-(4-ethylbenzylidene)-2-mercapto-1,3-thiazol-4(5H)-one; 5-[(4-Ethylphenyl)methylene]-2-thioxo-4-thiazolidinone; 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; 10058F4; (E)-5-(4-Ethylbenzylidene)-2-mercaptothiazol-4(5H)-one; c-Myc Inhibitor; 10058-F4 compound; 5-(4-ethylbenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one; CHEMBL1568415; SCHEMBL10042186; (Z,E)-5-(4-Ethylbenzylidine)-2-thioxothiazolidin-4-one; EX-A660; CHEBI:149696; HMS3260I13; ALBB-009118; Tox21_500046; MFCD00758517; MFCD04969046; NSC764582; s7153; ZINC12406714; (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one; AKOS000307369; AKOS003017633; CCG-221350; CS-3965; LP00046; NSC-764582; SB19479; SDCCGSBI-0633678.P001; NCGC00185994-01; NCGC00185994-10; NCGC00260731-01; AC-32727; AS-55984; HY-12702; c-Myc Inhibitor - CAS 403811-55-2; BB 0259511; SW219661-1; 10058-F4, >=98% (HPLC), solid; A13725; Y-1489; AB00084200-01; SR-01000208026; SR-01000208026-1; 5-(4-ethylbenzylidene)-2-mercapto-1,3-thiazol-4(5H)-one; 5-[(4-ethylphenyl)methylidene]-2-sulfanyl-4,5-dihydro-1,3-thiazol-4-one
    Click to Show/Hide
Molecular Type
Small molecule
Disease Acute myeloid leukemia [ICD-11: 2A60] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C12H11NOS2
PubChem CID
1271002
Canonical SMILES
CCC1=CC=C(C=C1)C=C2C(=O)NC(=S)S2
InChI
1S/C12H11NOS2/c1-2-8-3-5-9(6-4-8)7-10-11(14)13-12(15)16-10/h3-7H,2H2,1H3,(H,13,14,15)/b10-7+
InChIKey
SVXDHPADAXBMFB-JXMROGBWSA-N
CAS Number
CAS 403811-55-2
ChEBI ID
CHEBI:149696
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Cells derived from glioblastoma multiforme patients Glioblastoma multiforme Homo sapiens
                    In-vivo Model For in vivo experiments, CSCs (5 * 104 cells) were implanted intracranially into 10 week-old female C.B17-lcr SCID mice.
                    Experimental
                    Result(s)		 Arsenic trioxide drastically enhanced the anti-proliferative effect of 10058F4 but not apoptotic effects.
Target and Pathway
Target(s) Programmed cell death 1 ligand 1 (PD-L1)  Molecule Info  [3]
KEGG Pathway Cell adhesion molecules (CAMs) Click to Show/Hide
Reactome PD-1 signaling Click to Show/Hide
WikiPathways Costimulation by the CD28 family Click to Show/Hide
References
Reference 1 Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status. Int J Biochem Cell Biol. 2019 Mar;108:7-16.
Reference 2 Arsenic trioxide sensitizes glioblastoma to a myc inhibitor. PLoS One. 2015 Jun 3;10(6):e0128288.
Reference 3 Bisdemethoxycurcumin in combination with Alpha-PD-L1 antibody boosts immune response against bladder cancer. Onco Targets Ther. 2017 May 22;10:2675-2683.
 Download Picture         KEGG Link